Welcome to This Week in Rheumatology. This week we're covering 8 notable papers spanning early intervention strategies, the fundamental mechanisms of autoimmunity and fibrosis, and new data on lupus therapies. Let's dive in.

This week's papers:

1. Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial. — Nature medicine 2026
2. International expert consensus recommendations on standardised nomenclature of SSA/Ro (TROVE2/Ro60 and TRIM21/Ro52) autoantibodies in autoimmune diseases. — Annals of the rheumatic diseases 2026
3. Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial. — JAMA 2026
4. Natural killer cell immunotherapy reverses lung fibrosis by eliminating senescent fibroblasts. — Science translational medicine 2026
5. Anti-PAD4 antibodies link autoimmunity to PAD4 with CTL-associated rheumatoid arthritis. — Annals of the rheumatic diseases 2026
6. Targeting fibroblasts in immune mediated inflammatory diseases: a cellular basis for cure? — Rheumatology (Oxford, England) 2026
7. Innate lymphoid cells in rheumatoid arthritis as mediators of pathology and resolution. — Nature reviews. Rheumatology 2026
8. Whole blood transcriptome profiling in patients treated with deucravacitinib and novel mechanistic insights into TYK2 inhibition in lupus: results from a post hoc analysis of the PAISLEY SLE phase 2 trial. — Annals of the rheumatic diseases 2026

Listen at AudioScholar